Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Hepatocellular 3Recurrence 2Pleural Effusion, Malignant 2Mesothelioma, Malignant 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms 1NSCLC 1Myeloproliferative Disorders 1Multiple Myeloma 1Melanoma 1Lymphoma 1Lymphedema 1Leukemia, Myeloid, Chronic-Phase 1Immunoglobulin Light-chain Amyloidosis 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Glioblastoma 1Fibrosis 1Fallopian Tube Neoplasms 1Dysplastic Nevus Syndrome 1Cholangiocarcinoma 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 42Carboplatin 37Bevacizumab 29liposomal doxorubicin 20Taxes 18Specimen Handling 18pembrolizumab 16olaparib 16Magnetic Resonance Spectroscopy 16Gemcitabine 16Topotecan 13Immunoglobulin G 12Disulfides 12Biopsy 11niraparib 8mirvetuximab soravtansine 8Nivolumab 7Doxorubicin 7Cyclophosphamide 6Cisplatin 6Drug Therapy 5130-nm albumin-bound paclitaxel 5cemiplimab 4cediranib 4Letrozole 4Injections 4Docetaxel 41-dodecylpyridoxal 4sarilumab 3rucaparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × Pharmaceutical Preparations × 1 year × Clear all
NCT06690775 2025-12-23

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

TORL Biotherapeutics, LLC

Phase 2 Recruiting
230 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡